1393802-40-8Relevant academic research and scientific papers
COMBINATION TREATMENT COMPRISING ADMINISTRATION OF 2-AMINO-3,5,5-TRIFLUORO-3,4,5,6-TETRAHYDROPYRIDINES
-
Page/Page column 26; 27, (2017/03/08)
The present invention is directed to the combined use of BACE1 inhibitor of Formula (I) and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
2-Amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease
-
, (2015/09/22)
The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS
-
Paragraph 0178; 0179, (2013/03/26)
This invention relates to compounds of the formula wherein and R1 to R3 are as described herein, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as pharmaceuticals fo
1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS
-
Page/Page column 28; 29, (2012/09/10)
This invention relates to compounds of the formula wherein and R1 to R3 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or pr
